Global Neurological Disorder Drugs Market

Neurological Disorder Drugs Comprehensive Study by Type (Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Antihypertensive, Anticoagulants, Others), Application (Hospital, Clinic, Home), Sales Channel (Brick and Mortar Drug Stores, Online Drug Stores, Others), Disorder (Parkinson’s Disease, Alzheimer’s Disease, Epilepsy, Cerebrovascular Disease, Multiple Sclerosis, Others), End User (Adults, Children) Players and Region - Global Market Outlook to 2024

Neurological Disorder Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Neurological Disorder Drugs Market Overview:
A neurological disorder is any medical condition that affects the nervous system which includes the brain, spinal cord, and other nerves. Problems with the structure or function of any part of the nervous system can lead to a neurological disorder. According to the World health organization, more than 6 million people die because of stroke each year; over 80% of these deaths take place in low- and middle-income countries. More than 50 million people have epilepsy worldwide. It is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year - Alzheimer's disease is the most common cause of dementia and may contribute to 60–70% of cases. The prevalence of migraine is more than 10% worldwide Some of the key players profiled in the study are Novartis International AG (Switzerland), Johnson and Johnson (United States), GlaxoSmithKline (United Kingdom), Pfizer (United States), Amgen (United States), UCB (Belgium), Merck & Co (United States), Bayer (Germany), AstraZeneca and Boehringer Ingelheim (Germany).

On the basis of geography, the market of Neurological Disorder Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Sales Channel, the sub-segment i.e. Brick and Mortar Drug Stores will boost the Neurological Disorder Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disorder, the sub-segment i.e. Parkinson’s Disease will boost the Neurological Disorder Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Adults will boost the Neurological Disorder Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Presence of large geriatric population suffering from neurological problems like Alzheimer's disease and Parkinson’s disease
  • Increased awareness about available preventive drugs for diseases like dementia, epilepsy, multiple sclerosis and migraine, owing to advancements in drug technology

Market Trend
  • The rise in usage of Artificial intelligence and Machine Learning in the current care of neurological disorders

Restraints
  • Stringent government regulations for approval of drugs

Opportunities
  • Breakthrough research in neurological disorders can provide pharmaceuticals companies with increased opportunities for their market growth
  • Growing neurological disorders worldwide can provide emerging prospects for drug retailers

Challenges
  • Research and development initiatives for drug formulations are expensive
  • Provision of affordable drugs inconsideration with developing and underdeveloped countries


Major Market Developments:

In December 2019, The U.S. Food and Drug Administration approved Ubrelvy (ubrogepant) tablets for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults and In November 2019, Philips launched Philips Intellispace Cognition, the digital, cloud-based assessment tool that takes established neuropsychological tests and enables their administration by a medical assistant via a tablet in an office setting
In June 2019, Pfizer acquired Array BioPharma expanding its operations in the United States

The Neurological Disorder Drugs market is highly fragmented with the presence of many players worldwide. Some of the leading players are adopting some organic and inorganic strategies such as a merger, acquisition, expansion, new product launches, among others in order to gain leading share within the market. There are scopes for expansion with the surge in new improved products being launched owing to technological advancements

Target Audience:
Pharmaceutical Companies, Pharmacy Chains/Drug Stores, Drug Suppliers/Traders, Drug Exporters/Importers, Investors, Regulatory and Government Bodies, Upstream Vendors, Downstream Vendors and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Neurological Disorder Drugs market on the basis of product [Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Antihypertensive, Anticoagulants and Others] , application [Hospital, Clinic and Home], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Neurological Disorder Drugs market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Neurological Disorder Drugs industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Neurocrine Biosciences (United States), Biogen (United States), Eli Lilly and Company (United States), Ionis Pharmaceuticals (United States), Adamas Pharmaceuticals (United States), BioMarin Pharmaceutical (United States), Otsuka America Pharmaceutical (United States) and AstraZeneca (United States).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Neurological Disorder Drugs market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.

Report Objectives / Segmentation Covered

By Type
  • Antipsychotic
  • Antiepileptic
  • Anticholinergic
  • Analgesics
  • Hypnotic and Sedative
  • Antihypertensive
  • Anticoagulants
  • Others
By Application
  • Hospital
  • Clinic
  • Home
By Sales Channel
  • Brick and Mortar Drug Stores
  • Online Drug Stores
  • Others

By Disorder
  • Parkinson’s Disease
  • Alzheimer’s Disease
  • Epilepsy
  • Cerebrovascular Disease
  • Multiple Sclerosis
  • Others

By End User
  • Adults
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Presence of large geriatric population suffering from neurological problems like Alzheimer's disease and Parkinson’s disease
      • 3.2.2. Increased awareness about available preventive drugs for diseases like dementia, epilepsy, multiple sclerosis and migraine, owing to advancements in drug technology
    • 3.3. Market Challenges
      • 3.3.1. Research and development initiatives for drug formulations are expensive
      • 3.3.2. Provision of affordable drugs inconsideration with developing and underdeveloped countries
    • 3.4. Market Trends
      • 3.4.1. The rise in usage of Artificial intelligence and Machine Learning in the current care of neurological disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Neurological Disorder Drugs, by Type, Application, Sales Channel, Disorder, End User and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Neurological Disorder Drugs (Value)
      • 5.2.1. Global Neurological Disorder Drugs by: Type (Value)
        • 5.2.1.1. Antipsychotic
        • 5.2.1.2. Antiepileptic
        • 5.2.1.3. Anticholinergic
        • 5.2.1.4. Analgesics
        • 5.2.1.5. Hypnotic and Sedative
        • 5.2.1.6. Antihypertensive
        • 5.2.1.7. Anticoagulants
        • 5.2.1.8. Others
      • 5.2.2. Global Neurological Disorder Drugs by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Home
      • 5.2.3. Global Neurological Disorder Drugs by: Sales Channel (Value)
        • 5.2.3.1. Brick and Mortar Drug Stores
        • 5.2.3.2. Online Drug Stores
        • 5.2.3.3. Others
      • 5.2.4. Global Neurological Disorder Drugs by: Disorder (Value)
        • 5.2.4.1. Parkinson’s Disease
        • 5.2.4.2. Alzheimer’s Disease
        • 5.2.4.3. Epilepsy
        • 5.2.4.4. Cerebrovascular Disease
        • 5.2.4.5. Multiple Sclerosis
        • 5.2.4.6. Others
      • 5.2.5. Global Neurological Disorder Drugs by: End User (Value)
        • 5.2.5.1. Adults
        • 5.2.5.2. Children
      • 5.2.6. Global Neurological Disorder Drugs Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Neurological Disorder Drugs (Volume)
      • 5.3.1. Global Neurological Disorder Drugs by: Type (Volume)
        • 5.3.1.1. Antipsychotic
        • 5.3.1.2. Antiepileptic
        • 5.3.1.3. Anticholinergic
        • 5.3.1.4. Analgesics
        • 5.3.1.5. Hypnotic and Sedative
        • 5.3.1.6. Antihypertensive
        • 5.3.1.7. Anticoagulants
        • 5.3.1.8. Others
      • 5.3.2. Global Neurological Disorder Drugs by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinic
        • 5.3.2.3. Home
      • 5.3.3. Global Neurological Disorder Drugs by: Sales Channel (Volume)
        • 5.3.3.1. Brick and Mortar Drug Stores
        • 5.3.3.2. Online Drug Stores
        • 5.3.3.3. Others
      • 5.3.4. Global Neurological Disorder Drugs by: Disorder (Volume)
        • 5.3.4.1. Parkinson’s Disease
        • 5.3.4.2. Alzheimer’s Disease
        • 5.3.4.3. Epilepsy
        • 5.3.4.4. Cerebrovascular Disease
        • 5.3.4.5. Multiple Sclerosis
        • 5.3.4.6. Others
      • 5.3.5. Global Neurological Disorder Drugs by: End User (Volume)
        • 5.3.5.1. Adults
        • 5.3.5.2. Children
      • 5.3.6. Global Neurological Disorder Drugs Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Neurological Disorder Drugs (Price)
      • 5.4.1. Global Neurological Disorder Drugs by: Type (Price)
  • 6. Neurological Disorder Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson and Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Amgen (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. UCB (Belgium)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck & Co (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bayer (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boehringer Ingelheim (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Neurological Disorder Drugs Sale, by Type, Application, Sales Channel, Disorder, End User and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Neurological Disorder Drugs (Value)
      • 7.2.1. Global Neurological Disorder Drugs by: Type (Value)
        • 7.2.1.1. Antipsychotic
        • 7.2.1.2. Antiepileptic
        • 7.2.1.3. Anticholinergic
        • 7.2.1.4. Analgesics
        • 7.2.1.5. Hypnotic and Sedative
        • 7.2.1.6. Antihypertensive
        • 7.2.1.7. Anticoagulants
        • 7.2.1.8. Others
      • 7.2.2. Global Neurological Disorder Drugs by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Home
      • 7.2.3. Global Neurological Disorder Drugs by: Sales Channel (Value)
        • 7.2.3.1. Brick and Mortar Drug Stores
        • 7.2.3.2. Online Drug Stores
        • 7.2.3.3. Others
      • 7.2.4. Global Neurological Disorder Drugs by: Disorder (Value)
        • 7.2.4.1. Parkinson’s Disease
        • 7.2.4.2. Alzheimer’s Disease
        • 7.2.4.3. Epilepsy
        • 7.2.4.4. Cerebrovascular Disease
        • 7.2.4.5. Multiple Sclerosis
        • 7.2.4.6. Others
      • 7.2.5. Global Neurological Disorder Drugs by: End User (Value)
        • 7.2.5.1. Adults
        • 7.2.5.2. Children
      • 7.2.6. Global Neurological Disorder Drugs Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Neurological Disorder Drugs (Volume)
      • 7.3.1. Global Neurological Disorder Drugs by: Type (Volume)
        • 7.3.1.1. Antipsychotic
        • 7.3.1.2. Antiepileptic
        • 7.3.1.3. Anticholinergic
        • 7.3.1.4. Analgesics
        • 7.3.1.5. Hypnotic and Sedative
        • 7.3.1.6. Antihypertensive
        • 7.3.1.7. Anticoagulants
        • 7.3.1.8. Others
      • 7.3.2. Global Neurological Disorder Drugs by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinic
        • 7.3.2.3. Home
      • 7.3.3. Global Neurological Disorder Drugs by: Sales Channel (Volume)
        • 7.3.3.1. Brick and Mortar Drug Stores
        • 7.3.3.2. Online Drug Stores
        • 7.3.3.3. Others
      • 7.3.4. Global Neurological Disorder Drugs by: Disorder (Volume)
        • 7.3.4.1. Parkinson’s Disease
        • 7.3.4.2. Alzheimer’s Disease
        • 7.3.4.3. Epilepsy
        • 7.3.4.4. Cerebrovascular Disease
        • 7.3.4.5. Multiple Sclerosis
        • 7.3.4.6. Others
      • 7.3.5. Global Neurological Disorder Drugs by: End User (Volume)
        • 7.3.5.1. Adults
        • 7.3.5.2. Children
      • 7.3.6. Global Neurological Disorder Drugs Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Neurological Disorder Drugs (Price)
      • 7.4.1. Global Neurological Disorder Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neurological Disorder Drugs: by Type(USD Million)
  • Table 2. Neurological Disorder Drugs Antipsychotic , by Region USD Million (2013-2018)
  • Table 3. Neurological Disorder Drugs Antiepileptic , by Region USD Million (2013-2018)
  • Table 4. Neurological Disorder Drugs Anticholinergic , by Region USD Million (2013-2018)
  • Table 5. Neurological Disorder Drugs Analgesics , by Region USD Million (2013-2018)
  • Table 6. Neurological Disorder Drugs Hypnotic and Sedative , by Region USD Million (2013-2018)
  • Table 7. Neurological Disorder Drugs Antihypertensive , by Region USD Million (2013-2018)
  • Table 8. Neurological Disorder Drugs Anticoagulants , by Region USD Million (2013-2018)
  • Table 9. Neurological Disorder Drugs Others , by Region USD Million (2013-2018)
  • Table 10. Neurological Disorder Drugs: by Application(USD Million)
  • Table 11. Neurological Disorder Drugs Hospital , by Region USD Million (2013-2018)
  • Table 12. Neurological Disorder Drugs Clinic , by Region USD Million (2013-2018)
  • Table 13. Neurological Disorder Drugs Home , by Region USD Million (2013-2018)
  • Table 14. Neurological Disorder Drugs: by Sales Channel(USD Million)
  • Table 15. Neurological Disorder Drugs Brick and Mortar Drug Stores , by Region USD Million (2013-2018)
  • Table 16. Neurological Disorder Drugs Online Drug Stores , by Region USD Million (2013-2018)
  • Table 17. Neurological Disorder Drugs Others , by Region USD Million (2013-2018)
  • Table 18. Neurological Disorder Drugs: by Disorder(USD Million)
  • Table 19. Neurological Disorder Drugs Parkinson’s Disease , by Region USD Million (2013-2018)
  • Table 20. Neurological Disorder Drugs Alzheimer’s Disease , by Region USD Million (2013-2018)
  • Table 21. Neurological Disorder Drugs Epilepsy , by Region USD Million (2013-2018)
  • Table 22. Neurological Disorder Drugs Cerebrovascular Disease , by Region USD Million (2013-2018)
  • Table 23. Neurological Disorder Drugs Multiple Sclerosis , by Region USD Million (2013-2018)
  • Table 24. Neurological Disorder Drugs Others , by Region USD Million (2013-2018)
  • Table 25. Neurological Disorder Drugs: by End User(USD Million)
  • Table 26. Neurological Disorder Drugs Adults , by Region USD Million (2013-2018)
  • Table 27. Neurological Disorder Drugs Children , by Region USD Million (2013-2018)
  • Table 28. South America Neurological Disorder Drugs, by Country USD Million (2013-2018)
  • Table 29. South America Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 30. South America Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 31. South America Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 32. South America Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 33. South America Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 34. Brazil Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 35. Brazil Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 36. Brazil Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 37. Brazil Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 38. Brazil Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 39. Argentina Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 40. Argentina Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 41. Argentina Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 42. Argentina Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 43. Argentina Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 44. Rest of South America Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 45. Rest of South America Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 46. Rest of South America Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 47. Rest of South America Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 48. Rest of South America Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 49. Asia Pacific Neurological Disorder Drugs, by Country USD Million (2013-2018)
  • Table 50. Asia Pacific Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 51. Asia Pacific Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 52. Asia Pacific Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 53. Asia Pacific Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 54. Asia Pacific Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 55. China Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 56. China Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 57. China Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 58. China Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 59. China Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 60. Japan Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 61. Japan Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 62. Japan Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 63. Japan Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 64. Japan Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 65. India Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 66. India Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 67. India Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 68. India Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 69. India Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 70. South Korea Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 71. South Korea Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 72. South Korea Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 73. South Korea Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 74. South Korea Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 75. Taiwan Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 76. Taiwan Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 77. Taiwan Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 78. Taiwan Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 79. Taiwan Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 80. Australia Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 81. Australia Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 82. Australia Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 83. Australia Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 84. Australia Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 85. Rest of Asia-Pacific Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 86. Rest of Asia-Pacific Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 87. Rest of Asia-Pacific Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 88. Rest of Asia-Pacific Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 89. Rest of Asia-Pacific Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 90. Europe Neurological Disorder Drugs, by Country USD Million (2013-2018)
  • Table 91. Europe Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 92. Europe Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 93. Europe Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 94. Europe Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 95. Europe Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 96. Germany Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 97. Germany Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 98. Germany Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 99. Germany Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 100. Germany Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 101. France Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 102. France Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 103. France Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 104. France Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 105. France Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 106. Italy Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 107. Italy Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 108. Italy Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 109. Italy Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 110. Italy Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 111. United Kingdom Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 112. United Kingdom Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 113. United Kingdom Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 114. United Kingdom Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 115. United Kingdom Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 116. Netherlands Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 117. Netherlands Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 118. Netherlands Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 119. Netherlands Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 120. Netherlands Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 121. Rest of Europe Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 122. Rest of Europe Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 123. Rest of Europe Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 124. Rest of Europe Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 125. Rest of Europe Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 126. MEA Neurological Disorder Drugs, by Country USD Million (2013-2018)
  • Table 127. MEA Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 128. MEA Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 129. MEA Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 130. MEA Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 131. MEA Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 132. Middle East Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 133. Middle East Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 134. Middle East Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 135. Middle East Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 136. Middle East Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 137. Africa Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 138. Africa Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 139. Africa Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 140. Africa Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 141. Africa Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 142. North America Neurological Disorder Drugs, by Country USD Million (2013-2018)
  • Table 143. North America Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 144. North America Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 145. North America Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 146. North America Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 147. North America Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 148. United States Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 149. United States Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 150. United States Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 151. United States Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 152. United States Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 153. Canada Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 154. Canada Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 155. Canada Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 156. Canada Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 157. Canada Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 158. Mexico Neurological Disorder Drugs, by Type USD Million (2013-2018)
  • Table 159. Mexico Neurological Disorder Drugs, by Application USD Million (2013-2018)
  • Table 160. Mexico Neurological Disorder Drugs, by Sales Channel USD Million (2013-2018)
  • Table 161. Mexico Neurological Disorder Drugs, by Disorder USD Million (2013-2018)
  • Table 162. Mexico Neurological Disorder Drugs, by End User USD Million (2013-2018)
  • Table 163. Neurological Disorder Drugs Sales: by Type(K Units)
  • Table 164. Neurological Disorder Drugs Sales Antipsychotic , by Region K Units (2013-2018)
  • Table 165. Neurological Disorder Drugs Sales Antiepileptic , by Region K Units (2013-2018)
  • Table 166. Neurological Disorder Drugs Sales Anticholinergic , by Region K Units (2013-2018)
  • Table 167. Neurological Disorder Drugs Sales Analgesics , by Region K Units (2013-2018)
  • Table 168. Neurological Disorder Drugs Sales Hypnotic and Sedative , by Region K Units (2013-2018)
  • Table 169. Neurological Disorder Drugs Sales Antihypertensive , by Region K Units (2013-2018)
  • Table 170. Neurological Disorder Drugs Sales Anticoagulants , by Region K Units (2013-2018)
  • Table 171. Neurological Disorder Drugs Sales Others , by Region K Units (2013-2018)
  • Table 172. Neurological Disorder Drugs Sales: by Application(K Units)
  • Table 173. Neurological Disorder Drugs Sales Hospital , by Region K Units (2013-2018)
  • Table 174. Neurological Disorder Drugs Sales Clinic , by Region K Units (2013-2018)
  • Table 175. Neurological Disorder Drugs Sales Home , by Region K Units (2013-2018)
  • Table 176. Neurological Disorder Drugs Sales: by Sales Channel(K Units)
  • Table 177. Neurological Disorder Drugs Sales Brick and Mortar Drug Stores , by Region K Units (2013-2018)
  • Table 178. Neurological Disorder Drugs Sales Online Drug Stores , by Region K Units (2013-2018)
  • Table 179. Neurological Disorder Drugs Sales Others , by Region K Units (2013-2018)
  • Table 180. Neurological Disorder Drugs Sales: by Disorder(K Units)
  • Table 181. Neurological Disorder Drugs Sales Parkinson’s Disease , by Region K Units (2013-2018)
  • Table 182. Neurological Disorder Drugs Sales Alzheimer’s Disease , by Region K Units (2013-2018)
  • Table 183. Neurological Disorder Drugs Sales Epilepsy , by Region K Units (2013-2018)
  • Table 184. Neurological Disorder Drugs Sales Cerebrovascular Disease , by Region K Units (2013-2018)
  • Table 185. Neurological Disorder Drugs Sales Multiple Sclerosis , by Region K Units (2013-2018)
  • Table 186. Neurological Disorder Drugs Sales Others , by Region K Units (2013-2018)
  • Table 187. Neurological Disorder Drugs Sales: by End User(K Units)
  • Table 188. Neurological Disorder Drugs Sales Adults , by Region K Units (2013-2018)
  • Table 189. Neurological Disorder Drugs Sales Children , by Region K Units (2013-2018)
  • Table 190. South America Neurological Disorder Drugs Sales, by Country K Units (2013-2018)
  • Table 191. South America Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 192. South America Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 193. South America Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 194. South America Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 195. South America Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 196. Brazil Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 197. Brazil Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 198. Brazil Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 199. Brazil Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 200. Brazil Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 201. Argentina Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 202. Argentina Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 203. Argentina Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 204. Argentina Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 205. Argentina Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 206. Rest of South America Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 207. Rest of South America Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 208. Rest of South America Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 209. Rest of South America Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 210. Rest of South America Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 211. Asia Pacific Neurological Disorder Drugs Sales, by Country K Units (2013-2018)
  • Table 212. Asia Pacific Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 213. Asia Pacific Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 214. Asia Pacific Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 215. Asia Pacific Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 216. Asia Pacific Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 217. China Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 218. China Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 219. China Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 220. China Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 221. China Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 222. Japan Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 223. Japan Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 224. Japan Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 225. Japan Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 226. Japan Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 227. India Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 228. India Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 229. India Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 230. India Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 231. India Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 232. South Korea Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 233. South Korea Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 234. South Korea Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 235. South Korea Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 236. South Korea Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 237. Taiwan Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 238. Taiwan Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 239. Taiwan Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 240. Taiwan Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 241. Taiwan Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 242. Australia Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 243. Australia Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 244. Australia Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 245. Australia Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 246. Australia Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 247. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 248. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 249. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 250. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 251. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 252. Europe Neurological Disorder Drugs Sales, by Country K Units (2013-2018)
  • Table 253. Europe Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 254. Europe Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 255. Europe Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 256. Europe Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 257. Europe Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 258. Germany Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 259. Germany Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 260. Germany Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 261. Germany Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 262. Germany Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 263. France Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 264. France Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 265. France Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 266. France Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 267. France Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 268. Italy Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 269. Italy Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 270. Italy Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 271. Italy Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 272. Italy Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 273. United Kingdom Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 274. United Kingdom Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 275. United Kingdom Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 276. United Kingdom Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 277. United Kingdom Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 278. Netherlands Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 279. Netherlands Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 280. Netherlands Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 281. Netherlands Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 282. Netherlands Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 283. Rest of Europe Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 284. Rest of Europe Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 285. Rest of Europe Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 286. Rest of Europe Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 287. Rest of Europe Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 288. MEA Neurological Disorder Drugs Sales, by Country K Units (2013-2018)
  • Table 289. MEA Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 290. MEA Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 291. MEA Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 292. MEA Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 293. MEA Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 294. Middle East Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 295. Middle East Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 296. Middle East Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 297. Middle East Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 298. Middle East Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 299. Africa Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 300. Africa Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 301. Africa Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 302. Africa Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 303. Africa Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 304. North America Neurological Disorder Drugs Sales, by Country K Units (2013-2018)
  • Table 305. North America Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 306. North America Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 307. North America Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 308. North America Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 309. North America Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 310. United States Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 311. United States Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 312. United States Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 313. United States Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 314. United States Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 315. Canada Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 316. Canada Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 317. Canada Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 318. Canada Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 319. Canada Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 320. Mexico Neurological Disorder Drugs Sales, by Type K Units (2013-2018)
  • Table 321. Mexico Neurological Disorder Drugs Sales, by Application K Units (2013-2018)
  • Table 322. Mexico Neurological Disorder Drugs Sales, by Sales Channel K Units (2013-2018)
  • Table 323. Mexico Neurological Disorder Drugs Sales, by Disorder K Units (2013-2018)
  • Table 324. Mexico Neurological Disorder Drugs Sales, by End User K Units (2013-2018)
  • Table 325. Neurological Disorder Drugs: by Type(USD/Units)
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Company Basic Information, Sales Area and Its Competitors
  • Table 331. Company Basic Information, Sales Area and Its Competitors
  • Table 332. Company Basic Information, Sales Area and Its Competitors
  • Table 333. Company Basic Information, Sales Area and Its Competitors
  • Table 334. Company Basic Information, Sales Area and Its Competitors
  • Table 335. Company Basic Information, Sales Area and Its Competitors
  • Table 336. Neurological Disorder Drugs: by Type(USD Million)
  • Table 337. Neurological Disorder Drugs Antipsychotic , by Region USD Million (2019-2024)
  • Table 338. Neurological Disorder Drugs Antiepileptic , by Region USD Million (2019-2024)
  • Table 339. Neurological Disorder Drugs Anticholinergic , by Region USD Million (2019-2024)
  • Table 340. Neurological Disorder Drugs Analgesics , by Region USD Million (2019-2024)
  • Table 341. Neurological Disorder Drugs Hypnotic and Sedative , by Region USD Million (2019-2024)
  • Table 342. Neurological Disorder Drugs Antihypertensive , by Region USD Million (2019-2024)
  • Table 343. Neurological Disorder Drugs Anticoagulants , by Region USD Million (2019-2024)
  • Table 344. Neurological Disorder Drugs Others , by Region USD Million (2019-2024)
  • Table 345. Neurological Disorder Drugs: by Application(USD Million)
  • Table 346. Neurological Disorder Drugs Hospital , by Region USD Million (2019-2024)
  • Table 347. Neurological Disorder Drugs Clinic , by Region USD Million (2019-2024)
  • Table 348. Neurological Disorder Drugs Home , by Region USD Million (2019-2024)
  • Table 349. Neurological Disorder Drugs: by Sales Channel(USD Million)
  • Table 350. Neurological Disorder Drugs Brick and Mortar Drug Stores , by Region USD Million (2019-2024)
  • Table 351. Neurological Disorder Drugs Online Drug Stores , by Region USD Million (2019-2024)
  • Table 352. Neurological Disorder Drugs Others , by Region USD Million (2019-2024)
  • Table 353. Neurological Disorder Drugs: by Disorder(USD Million)
  • Table 354. Neurological Disorder Drugs Parkinson’s Disease , by Region USD Million (2019-2024)
  • Table 355. Neurological Disorder Drugs Alzheimer’s Disease , by Region USD Million (2019-2024)
  • Table 356. Neurological Disorder Drugs Epilepsy , by Region USD Million (2019-2024)
  • Table 357. Neurological Disorder Drugs Cerebrovascular Disease , by Region USD Million (2019-2024)
  • Table 358. Neurological Disorder Drugs Multiple Sclerosis , by Region USD Million (2019-2024)
  • Table 359. Neurological Disorder Drugs Others , by Region USD Million (2019-2024)
  • Table 360. Neurological Disorder Drugs: by End User(USD Million)
  • Table 361. Neurological Disorder Drugs Adults , by Region USD Million (2019-2024)
  • Table 362. Neurological Disorder Drugs Children , by Region USD Million (2019-2024)
  • Table 363. South America Neurological Disorder Drugs, by Country USD Million (2019-2024)
  • Table 364. South America Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 365. South America Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 366. South America Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 367. South America Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 368. South America Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 369. Brazil Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 370. Brazil Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 371. Brazil Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 372. Brazil Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 373. Brazil Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 374. Argentina Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 375. Argentina Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 376. Argentina Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 377. Argentina Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 378. Argentina Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 379. Rest of South America Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 380. Rest of South America Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 381. Rest of South America Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 382. Rest of South America Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 383. Rest of South America Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 384. Asia Pacific Neurological Disorder Drugs, by Country USD Million (2019-2024)
  • Table 385. Asia Pacific Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 386. Asia Pacific Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 387. Asia Pacific Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 388. Asia Pacific Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 389. Asia Pacific Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 390. China Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 391. China Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 392. China Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 393. China Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 394. China Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 395. Japan Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 396. Japan Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 397. Japan Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 398. Japan Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 399. Japan Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 400. India Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 401. India Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 402. India Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 403. India Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 404. India Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 405. South Korea Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 406. South Korea Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 407. South Korea Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 408. South Korea Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 409. South Korea Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 410. Taiwan Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 411. Taiwan Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 412. Taiwan Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 413. Taiwan Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 414. Taiwan Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 415. Australia Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 416. Australia Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 417. Australia Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 418. Australia Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 419. Australia Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 420. Rest of Asia-Pacific Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 421. Rest of Asia-Pacific Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 422. Rest of Asia-Pacific Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 423. Rest of Asia-Pacific Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 424. Rest of Asia-Pacific Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 425. Europe Neurological Disorder Drugs, by Country USD Million (2019-2024)
  • Table 426. Europe Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 427. Europe Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 428. Europe Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 429. Europe Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 430. Europe Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 431. Germany Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 432. Germany Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 433. Germany Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 434. Germany Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 435. Germany Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 436. France Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 437. France Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 438. France Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 439. France Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 440. France Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 441. Italy Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 442. Italy Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 443. Italy Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 444. Italy Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 445. Italy Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 446. United Kingdom Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 447. United Kingdom Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 448. United Kingdom Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 449. United Kingdom Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 450. United Kingdom Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 451. Netherlands Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 452. Netherlands Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 453. Netherlands Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 454. Netherlands Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 455. Netherlands Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 456. Rest of Europe Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 457. Rest of Europe Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 458. Rest of Europe Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 459. Rest of Europe Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 460. Rest of Europe Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 461. MEA Neurological Disorder Drugs, by Country USD Million (2019-2024)
  • Table 462. MEA Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 463. MEA Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 464. MEA Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 465. MEA Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 466. MEA Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 467. Middle East Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 468. Middle East Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 469. Middle East Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 470. Middle East Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 471. Middle East Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 472. Africa Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 473. Africa Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 474. Africa Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 475. Africa Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 476. Africa Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 477. North America Neurological Disorder Drugs, by Country USD Million (2019-2024)
  • Table 478. North America Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 479. North America Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 480. North America Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 481. North America Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 482. North America Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 483. United States Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 484. United States Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 485. United States Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 486. United States Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 487. United States Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 488. Canada Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 489. Canada Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 490. Canada Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 491. Canada Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 492. Canada Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 493. Mexico Neurological Disorder Drugs, by Type USD Million (2019-2024)
  • Table 494. Mexico Neurological Disorder Drugs, by Application USD Million (2019-2024)
  • Table 495. Mexico Neurological Disorder Drugs, by Sales Channel USD Million (2019-2024)
  • Table 496. Mexico Neurological Disorder Drugs, by Disorder USD Million (2019-2024)
  • Table 497. Mexico Neurological Disorder Drugs, by End User USD Million (2019-2024)
  • Table 498. Neurological Disorder Drugs Sales: by Type(K Units)
  • Table 499. Neurological Disorder Drugs Sales Antipsychotic , by Region K Units (2019-2024)
  • Table 500. Neurological Disorder Drugs Sales Antiepileptic , by Region K Units (2019-2024)
  • Table 501. Neurological Disorder Drugs Sales Anticholinergic , by Region K Units (2019-2024)
  • Table 502. Neurological Disorder Drugs Sales Analgesics , by Region K Units (2019-2024)
  • Table 503. Neurological Disorder Drugs Sales Hypnotic and Sedative , by Region K Units (2019-2024)
  • Table 504. Neurological Disorder Drugs Sales Antihypertensive , by Region K Units (2019-2024)
  • Table 505. Neurological Disorder Drugs Sales Anticoagulants , by Region K Units (2019-2024)
  • Table 506. Neurological Disorder Drugs Sales Others , by Region K Units (2019-2024)
  • Table 507. Neurological Disorder Drugs Sales: by Application(K Units)
  • Table 508. Neurological Disorder Drugs Sales Hospital , by Region K Units (2019-2024)
  • Table 509. Neurological Disorder Drugs Sales Clinic , by Region K Units (2019-2024)
  • Table 510. Neurological Disorder Drugs Sales Home , by Region K Units (2019-2024)
  • Table 511. Neurological Disorder Drugs Sales: by Sales Channel(K Units)
  • Table 512. Neurological Disorder Drugs Sales Brick and Mortar Drug Stores , by Region K Units (2019-2024)
  • Table 513. Neurological Disorder Drugs Sales Online Drug Stores , by Region K Units (2019-2024)
  • Table 514. Neurological Disorder Drugs Sales Others , by Region K Units (2019-2024)
  • Table 515. Neurological Disorder Drugs Sales: by Disorder(K Units)
  • Table 516. Neurological Disorder Drugs Sales Parkinson’s Disease , by Region K Units (2019-2024)
  • Table 517. Neurological Disorder Drugs Sales Alzheimer’s Disease , by Region K Units (2019-2024)
  • Table 518. Neurological Disorder Drugs Sales Epilepsy , by Region K Units (2019-2024)
  • Table 519. Neurological Disorder Drugs Sales Cerebrovascular Disease , by Region K Units (2019-2024)
  • Table 520. Neurological Disorder Drugs Sales Multiple Sclerosis , by Region K Units (2019-2024)
  • Table 521. Neurological Disorder Drugs Sales Others , by Region K Units (2019-2024)
  • Table 522. Neurological Disorder Drugs Sales: by End User(K Units)
  • Table 523. Neurological Disorder Drugs Sales Adults , by Region K Units (2019-2024)
  • Table 524. Neurological Disorder Drugs Sales Children , by Region K Units (2019-2024)
  • Table 525. South America Neurological Disorder Drugs Sales, by Country K Units (2019-2024)
  • Table 526. South America Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 527. South America Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 528. South America Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 529. South America Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 530. South America Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 531. Brazil Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 532. Brazil Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 533. Brazil Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 534. Brazil Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 535. Brazil Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 536. Argentina Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 537. Argentina Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 538. Argentina Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 539. Argentina Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 540. Argentina Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 541. Rest of South America Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 542. Rest of South America Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 543. Rest of South America Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 544. Rest of South America Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 545. Rest of South America Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 546. Asia Pacific Neurological Disorder Drugs Sales, by Country K Units (2019-2024)
  • Table 547. Asia Pacific Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 548. Asia Pacific Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 549. Asia Pacific Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 550. Asia Pacific Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 551. Asia Pacific Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 552. China Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 553. China Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 554. China Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 555. China Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 556. China Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 557. Japan Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 558. Japan Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 559. Japan Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 560. Japan Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 561. Japan Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 562. India Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 563. India Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 564. India Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 565. India Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 566. India Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 567. South Korea Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 568. South Korea Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 569. South Korea Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 570. South Korea Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 571. South Korea Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 572. Taiwan Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 573. Taiwan Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 574. Taiwan Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 575. Taiwan Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 576. Taiwan Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 577. Australia Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 578. Australia Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 579. Australia Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 580. Australia Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 581. Australia Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 582. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 583. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 584. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 585. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 586. Rest of Asia-Pacific Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 587. Europe Neurological Disorder Drugs Sales, by Country K Units (2019-2024)
  • Table 588. Europe Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 589. Europe Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 590. Europe Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 591. Europe Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 592. Europe Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 593. Germany Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 594. Germany Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 595. Germany Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 596. Germany Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 597. Germany Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 598. France Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 599. France Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 600. France Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 601. France Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 602. France Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 603. Italy Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 604. Italy Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 605. Italy Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 606. Italy Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 607. Italy Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 608. United Kingdom Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 609. United Kingdom Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 610. United Kingdom Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 611. United Kingdom Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 612. United Kingdom Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 613. Netherlands Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 614. Netherlands Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 615. Netherlands Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 616. Netherlands Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 617. Netherlands Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 618. Rest of Europe Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 619. Rest of Europe Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 620. Rest of Europe Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 621. Rest of Europe Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 622. Rest of Europe Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 623. MEA Neurological Disorder Drugs Sales, by Country K Units (2019-2024)
  • Table 624. MEA Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 625. MEA Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 626. MEA Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 627. MEA Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 628. MEA Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 629. Middle East Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 630. Middle East Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 631. Middle East Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 632. Middle East Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 633. Middle East Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 634. Africa Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 635. Africa Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 636. Africa Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 637. Africa Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 638. Africa Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 639. North America Neurological Disorder Drugs Sales, by Country K Units (2019-2024)
  • Table 640. North America Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 641. North America Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 642. North America Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 643. North America Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 644. North America Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 645. United States Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 646. United States Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 647. United States Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 648. United States Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 649. United States Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 650. Canada Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 651. Canada Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 652. Canada Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 653. Canada Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 654. Canada Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 655. Mexico Neurological Disorder Drugs Sales, by Type K Units (2019-2024)
  • Table 656. Mexico Neurological Disorder Drugs Sales, by Application K Units (2019-2024)
  • Table 657. Mexico Neurological Disorder Drugs Sales, by Sales Channel K Units (2019-2024)
  • Table 658. Mexico Neurological Disorder Drugs Sales, by Disorder K Units (2019-2024)
  • Table 659. Mexico Neurological Disorder Drugs Sales, by End User K Units (2019-2024)
  • Table 660. Neurological Disorder Drugs: by Type(USD/Units)
  • Table 661. Research Programs/Design for This Report
  • Table 662. Key Data Information from Secondary Sources
  • Table 663. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Neurological Disorder Drugs: by Type USD Million (2013-2018)
  • Figure 5. Global Neurological Disorder Drugs: by Application USD Million (2013-2018)
  • Figure 6. Global Neurological Disorder Drugs: by Sales Channel USD Million (2013-2018)
  • Figure 7. Global Neurological Disorder Drugs: by Disorder USD Million (2013-2018)
  • Figure 8. Global Neurological Disorder Drugs: by End User USD Million (2013-2018)
  • Figure 9. South America Neurological Disorder Drugs Share (%), by Country
  • Figure 10. Asia Pacific Neurological Disorder Drugs Share (%), by Country
  • Figure 11. Europe Neurological Disorder Drugs Share (%), by Country
  • Figure 12. MEA Neurological Disorder Drugs Share (%), by Country
  • Figure 13. North America Neurological Disorder Drugs Share (%), by Country
  • Figure 14. Global Neurological Disorder Drugs: by Type K Units (2013-2018)
  • Figure 15. Global Neurological Disorder Drugs: by Application K Units (2013-2018)
  • Figure 16. Global Neurological Disorder Drugs: by Sales Channel K Units (2013-2018)
  • Figure 17. Global Neurological Disorder Drugs: by Disorder K Units (2013-2018)
  • Figure 18. Global Neurological Disorder Drugs: by End User K Units (2013-2018)
  • Figure 19. South America Neurological Disorder Drugs Share (%), by Country
  • Figure 20. Asia Pacific Neurological Disorder Drugs Share (%), by Country
  • Figure 21. Europe Neurological Disorder Drugs Share (%), by Country
  • Figure 22. MEA Neurological Disorder Drugs Share (%), by Country
  • Figure 23. North America Neurological Disorder Drugs Share (%), by Country
  • Figure 24. Global Neurological Disorder Drugs: by Type USD/Units (2013-2018)
  • Figure 25. Global Neurological Disorder Drugs share by Players 2018 (%)
  • Figure 26. Global Neurological Disorder Drugs share by Players (Top 3) 2018(%)
  • Figure 27. Global Neurological Disorder Drugs share by Players (Top 5) 2018(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis International AG (Switzerland) Revenue: by Geography 2018
  • Figure 31. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson and Johnson (United States) Revenue: by Geography 2018
  • Figure 33. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 35. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer (United States) Revenue: by Geography 2018
  • Figure 37. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 38. Amgen (United States) Revenue: by Geography 2018
  • Figure 39. UCB (Belgium) Revenue, Net Income and Gross profit
  • Figure 40. UCB (Belgium) Revenue: by Geography 2018
  • Figure 41. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 42. Merck & Co (United States) Revenue: by Geography 2018
  • Figure 43. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Bayer (Germany) Revenue: by Geography 2018
  • Figure 45. AstraZeneca Revenue, Net Income and Gross profit
  • Figure 46. AstraZeneca Revenue: by Geography 2018
  • Figure 47. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 48. Boehringer Ingelheim (Germany) Revenue: by Geography 2018
  • Figure 49. Global Neurological Disorder Drugs: by Type USD Million (2019-2024)
  • Figure 50. Global Neurological Disorder Drugs: by Application USD Million (2019-2024)
  • Figure 51. Global Neurological Disorder Drugs: by Sales Channel USD Million (2019-2024)
  • Figure 52. Global Neurological Disorder Drugs: by Disorder USD Million (2019-2024)
  • Figure 53. Global Neurological Disorder Drugs: by End User USD Million (2019-2024)
  • Figure 54. South America Neurological Disorder Drugs Share (%), by Country
  • Figure 55. Asia Pacific Neurological Disorder Drugs Share (%), by Country
  • Figure 56. Europe Neurological Disorder Drugs Share (%), by Country
  • Figure 57. MEA Neurological Disorder Drugs Share (%), by Country
  • Figure 58. North America Neurological Disorder Drugs Share (%), by Country
  • Figure 59. Global Neurological Disorder Drugs: by Type K Units (2019-2024)
  • Figure 60. Global Neurological Disorder Drugs: by Application K Units (2019-2024)
  • Figure 61. Global Neurological Disorder Drugs: by Sales Channel K Units (2019-2024)
  • Figure 62. Global Neurological Disorder Drugs: by Disorder K Units (2019-2024)
  • Figure 63. Global Neurological Disorder Drugs: by End User K Units (2019-2024)
  • Figure 64. South America Neurological Disorder Drugs Share (%), by Country
  • Figure 65. Asia Pacific Neurological Disorder Drugs Share (%), by Country
  • Figure 66. Europe Neurological Disorder Drugs Share (%), by Country
  • Figure 67. MEA Neurological Disorder Drugs Share (%), by Country
  • Figure 68. North America Neurological Disorder Drugs Share (%), by Country
  • Figure 69. Global Neurological Disorder Drugs: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Johnson and Johnson (United States)
  • GlaxoSmithKline (United Kingdom)
  • Pfizer (United States)
  • Amgen (United States)
  • UCB (Belgium)
  • Merck & Co (United States)
  • Bayer (Germany)
  • AstraZeneca
  • Boehringer Ingelheim (Germany)
Additional players considered in the study are as follows:
Neurocrine Biosciences (United States) , Biogen (United States) , Eli Lilly and Company (United States) , Ionis Pharmaceuticals (United States) , Adamas Pharmaceuticals (United States) , BioMarin Pharmaceutical (United States) , Otsuka America Pharmaceutical (United States) , AstraZeneca (United States)
Select User Access Type

Key Highlights of Report


Feb 2020 221 Pages 85 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Neurological Disorder Drugs Market Quantitative research analysis
Global Neurological Disorder Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Neurological Disorder Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Glycopyrrolate Comprehensive Study by Application (Hospitals, Clinics), Form (Tablet, Solution), Sales Channel (Offline (Pharma Stores, Medical Outlets), Online (E-commerce)) Players and Region - Glo...
$ 3500
Levodopa Comprehensive Study by Application (Pharmaceuticals Industry, Dietary Supplements), Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies) Players and Region - Gl...
$ 3500
Argatroban Comprehensive Study by Type (Argatroban Powder, Argatroban Injection), Application (Heparin-induced Thrombocytopenia (HIT), Percutaneous Coronary Intervention, Cerebral Arterial Thrombosis...
$ 3450
Deferasirox Comprehensive Study by Type (Tablets, Suspension, Granules, Others), Application (Transfusional Iron Overload, Non-Transfusional Iron Overload, Others), Distribution Channel (Pharmacy Sto...
$ 3650
Varicella Vaccine Comprehensive Study by Type (Monovalent Varicella Vaccine, Combination Varicella Vaccine), Application (Pharmaceutical & Healthcare Products, Food & Beverages, Household & Personal ...
$ 3750
Biologics Comprehensive Study by Type (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Other), Application (Cancer, Infectious Diseases...
$ 3800